Amgen names replacements for two top execs

27 July 2018

Along with announcing analysts’ expectation-beating financials, leading biotech firm Amgen's (Nasdaq: AMGN) outlined planned executive succession to address upcoming departures of two executive vice presidents.

After more than 21 years of leadership in the biopharmaceutical industry, including the past 16 years with Amgen, Sean Harper, executive vice president of Research and Development, has decided to retire and plans to pursue opportunities in the early-stage biotechnology community.

David Reese, currently senior VP of translational sciences and oncology at Amgen, has been appointed as EVP of Research and Development, effective Thursday. Dr Reese will report to Robert Bradway, chairman and chief executive officer. Dr Harper will remain at Amgen for a period of time to facilitate the transition to Reese.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK